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Group sequential designs are used to potentially
shorten randomized clinical trials and thereby reduce
subject burden, improve safety, and save time and
resources. Clinical trials comparing treatments for
systemic lupus erythematosus (SLE) might adopt such
designs if the ordinal outcome scales for SLE, such as
the Systemic Lupus Activity Measure and Systemic
Lupus Erythematosus Disease Activity Index, were
more like continuous outcome scales with interval
properties. After describing the basic features of
sequential trials and highlighting some major issues in
their design, we propose approaches that mitigate
these issues. In particular, high-speed computing has
accelerated advances in sequential design, making
available a variety of designs that can be implemented
with minimal technical support. The challenge now
is to understand the concepts behind such flexible
designs and then to apply them to improve studies
of SLE.from n to n + 1, may vary depending on the value of n.Introduction
Terminating a clinical trial as soon as a robust result
becomes evident is an ethical and practical imperative
and minimizes exposure of volunteer participants to po-
tentially ineffective or toxic treatment. Group sequential
clinical trial designs are a means to this end. This paper
discusses and outlines the process and the methods of
sequential designs in systemic lupus erythematosus
(SLE), a disease like no other in its protean and variable
manifestations. To the best of our knowledge no one has* Correspondence: Robert.lew2@va.gov
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reason may be that many SLE outcome measures have
ordinal rather than interval properties. Ideally, a sequen-
tial trial should have an a priori definition of clinically
meaningful change on an interval scale. We propose
methods to transform an ordinal measure into a mea-
sure closer to this ideal. Studies in the systemic rheum-
atic conditions have employed composite outcome scales
to capture the full impact of these illnesses on the indi-
vidual. These combine levels of disability, symptoms,
and physiological biomarkers. Such disparate elements
do not simply add up, but are combined into an ordinal
scale with or without weights. The weighting may be
done implicitly or inferred indirectly by expert clinicians.
Compared with continuous outcome measures, ordinal
measures such as the British Isles Lupus Assessment
Group (BILAG), Systemic Lupus Activity Measure
(SLAM) and Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI) [1] are not optimal for tracking
the progression of disease over time. The clinical im-
portance of a change of one unit in an ordinal scale,
Ideally, if comparing mean treatment effects with
Student’s t-test, the difference between means should
have an unambiguous clinical interpretation, regardless
of the particular mean values.
Continuous measures, however, also fall short. For ex-
ample, a decrease in systolic blood pressure from 240 to
200 mm Hg has a different meaning and clinical signifi-
cance than a decrease from 140 to 100 mm Hg. There-
fore, both the absolute and the relative changes are
needed to interpret a 40 mm Hg blood pressure drop.
This paper addresses this problem in the context of a
sequential randomized clinical trial. Simple ‘one-stop’
trials have a fixed study period, such as 1 year, when
they stop and test the null hypothesis that treatment
effects are equal. Typical sequential trials plan on testing
the null hypothesis several times during the studydistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Lew et al. Arthritis Research & Therapy  (2015) 17:345 Page 2 of 7period; for example, a 1-year study might test at 3, 6, 9,
and finally 12 months. At each time-point, an interim
analysis is done to decide whether to stop or to continue
the trial. The study may stop early either because the
experimental treatment appears effective (and highly
statistically significant) or because it appears ineffective
and futile (with virtually no chance of reaching statistical
significance by the end of the study).
Interim analysis
Sequential analyses periodically test a null hypothesis
while the data accrue. Each interim test either stops or
continues the study. The theory of sequential analysis
largely originates with the work of Abraham Wald [2].
Driven out of Austria by the Nazis, his theoretical work
became the basis of mathematical statistics [3] and his
applied work led to major advances in manufacturing
quality control, insurance, and sequential analysis. His
work on the problem of WW2 bomber losses to enemy
fire [4] led to better strategies that reduced losses. In
medical research he showed how early stopping in a
clinical trial could preserve resources with just a few
more subjects than needed in a one-stop trial. Many ad-
vances in the design of sequential trials followed and
then accelerated once high-speed computing became
widely available. Chapter 1 of the Jennison and Turnbull
seminal text Group Sequential Trials traces the history
[5]. This text describes most of the methods currently
used by the pharmaceutical industry and in academic,
medical, and government organizations. Many designs
have become feasible because only with high-speed com-
puter simulation can one calculate power and type I
error. Figure 1 indicates why. Each opportunity to stop
the trial depends on all of the preceding decisions to
continue to accrue data. The corresponding equations
seldom have simple solutions.
Alpha spending
A simple ‘one-stop’ design performs only one test when
the trial ends, usually with 90 % power with a type I
error of 5 %. Type I error is also called ‘alpha level’ or
simply ‘alpha’. Sequential trials make several tests. We
cannot use alpha = 5 % (a type I error of 5 %) at every in-
terim analysis [6]. If we do so, as in Fig. 1, the actual
type I error is about 20 % = 4 × 5 %, far too large aFig. 1 The pattern of decisions in a sequential trialchance to mistakenly reject the null hypothesis. One
should regard type I error of 5 % as if it were alpha = $5
in a bank account. In Fig. 1, you might spend $1 of alpha
at each interim analysis and then spend $2 of alpha at
the end, so-called ‘alpha spending’ [7]. Studies with in-
terim analyses must distribute the type I error over all
the potential stopping times. The final test must have
type I error <5 % because some type I error was spent
earlier. Simulation allows one to explore a wide range of
spending plans to find an ‘optimal’ plan. No plan is
actually optimal because all choices involve tradeoffs
between minimal sample size and maximal power.Group sequential trials
Most clinical trials in SLE slowly accrue fewer than 10
patients from multiple sites during a year. For example,
consider a 100-day SLE clinical trial that enrolls one
patient per day. As in Fig. 1, interim analyses might
occur at 25, 50, and 75 days. If the treatment result is
immediate, then at 25 days we would analyze 25 results,
at 50 days 50 results, and so on. The results accrue in
groups of 25, hence the term ‘group sequential trials’.
Slow accrual of evaluable participants or those who
reach a pre-specified endpoint adds complexity. Firstly, to
avoid a hasty decision when the sample size is small, many
designs make it very hard to reject the null hypothesis at
the first interim analysis and gradually make it easier to
reject it at the later interim analyses. Secondly, treatment
outcomes in SLE are seldom immediate, so that, in the
example above, only some of the 25 enrolled may be eva-
luable on day 25, only some of the 50 enrolled evaluable
on day 50, and so on. Thirdly, survival (time-to-event)
analyses have to account for the varying amounts of
follow-up time. Substantial computer simulations can
search for an ‘optimal’ design that addresses all these is-
sues, but experienced clinicians must play a major role to
ensure the optimality criteria are practical and clinically
realistic [8].The O’Brien-Fleming design
Many sequential designs begin by assuming the test stat-
istic, such as the difference between means, has a nor-
mal distribution. If the two treatments are labeled ‘A’ and
‘B’, then at each interim analysis we would compare the
Fig. 2 Cutoff Z-values for stopping to reject the null hypothesis (H0), stopping for futility, or continuing
Table 1 Approximate extreme values of some ordinal outcome
scales for systemic lupus erythematosus
Scalea Minimum and maximum Description
SLAM 0 to 84 Systemic Lupus Activity Measure
SLEDAI 0 to 108 Systemic Lupus Erythematosus
Disease Activity Index
BILAG 0 to 180 British Isles Lupus Assessment Group
ECLAM 0 to 15.5 European Consensus Lupus Activity
Measure
aListing of items for each scale, and minimum and maximum scores obtained
from Lam and Petri [1]
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H0, is that the means do not differ, a zero difference. As
patients accrue, the standard error of each sample
mean tends to decrease. At each time let the dif-
ference be d ¼ b−a. Set z = d/sterr(d), where z is nor-
mally distributed with standard deviation 1 and sterr(d) is
the standard error of d. Thus, as in Fig. 1, for three interim
tests and one final test, if we did not stop early, during the
study we would have observed four differences and their
corresponding four observed z-scores, z1, z2, z3, and z4.
The hypothesis tests compare the observed z-scores to
pre-specified cutoff Z-values. For a one-stop test of hy-
pothesis with type I error of 5 % under the normal distri-
bution the typical cutoff Z-value for a significant result is
1.96, for which the probability P(−1.96 < z < 1.96) = 0.95.
Test statistics with values of z between the cutoff
values, −1.96 and 1.96, are not significant and those
with values outside this interval are significant.
Because of alpha-spending, all four z-cutoff values for a
sequential test must exceed 1.96. An overly safe set of
cutoff Z-values is 2.57, 2.57, 2.57, and 2.32 because
P(|z| ≥ 2.57) = 0.01, P(|z| ≥ 2.32) = 0.02, and the sum of
the four values of alpha would be 0.01 + 0.01 + 0.01 +
0.02 = 0.05. This ignores the fact that because the data
used to calculate each successive test statistic contain all
the previous data, the tests are positively correlated.
The O’Brien-Fleming rule starts with very a high cutoff
Z-value and then declines over time [5]. For this example,
the four cutoff Z-values are 4.048, 2.862, 2.337, and finally
2.024 [5]. By starting so high at 4.048, we spend very little
alpha. Thus, we can finish at 2.024, a cutoff Z-value not
much larger than 1.96. Ignoring the positive correlation,
the corresponding sum of alpha values is 0.001 + 0.004 +
0.019 + 0.042 = 0.066. Fortunately, because the O’Brien-
Fleming rule accounts for this correlation, the actual over-
all type I error is 5 %, even though the sum of the alpha
values is 6.6 %. We pay for this with a small increase in
total sample size; if a one-stop design needs 1000 subjects,
then this sequential design needs 1024 subjects, a 2.4 %
increase. Tables listing the cutoff Z-values and the in-
creases in sample size appear in the Jennison and Turn-
bull text [5] along with explanatory material and
examples. Also, one may obtain these values from PROC
Seqdesign in the SAS statistical package (SAS version 9.3,
SAS Institute Inc., Cary, NC, USA) and the program Clin-
fun in the R language online library of functions [9].Applied to the design in Fig. 1, the O’Brien-Fleming
test increases sample size, but provides three chances to
stop early, but not for futility—that is, stopping early be-
cause the treatment difference is so small that gathering
more data as planned has little or no chance to reject
the null hypothesis [5]. More often than not, treatment
differences are smaller than expected and seldom much
larger than expected. Thus, in many studies an O’Brien-
Fleming design with a very conservative option to stop
for futility can shorten a study and save a lot of
resources.
Bayesian designs
High-speed computing allows us to explore many sets of
cutoff Z-values to either reject the null hypothesis or de-
clare futility. The Bayesian approach to design allows
such a flexible approach, but adds terminology and
intensive computation. Futility becomes easier to in-
corporate into the design [10, 11]. The logic of Bayesian
inference for sequential designs resembles the logic of
differential diagnosis and ‘trials of therapy’ when a
physician works through a sequence of treatments with
a patient until by trial and error they find the most
effective treatment.
For Bayesian designs, however, physicians must specify
prior opinions or beliefs about a meaningful difference
between treatment effects, a challenging issue when
using ordinal scales to score overall SLE manifestations
or disease activity. To avoid bias it is critical to blind
outcome assessment of subjectively rated phenomena.
Therefore, Bayesian analysis requires ‘model criticism’,
an exploration of a wide range of prior assumptions to
confirm or not confirm the results of the treatment
Table 2 The seven categories of the modified Rankin score and an associated utility score
Modified Rankin score value
0 1 2 3 4 5 6











Utilitya 100 90 70 50 30 1 1
aThese utilities are fabricated. mRS, modified Rankin score
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from a statistician and very complex computer simulation.
Futility adds a second set of cutoff Z-values that are
close to zero, indicative of a small difference between
treatment means. In the Fig. 1 example, if the third in-
terim analysis occurred at 9 months, we might reject the
null hypothesis, H0, if the absolute value of the observed
z-score is >2.34, accept H0 if <0.07 (a typical value
for a futility cutoff ), or continue. The 9-month cutoff
Z-values partition the interval into five subintervals as
in Fig. 2.
The term ‘ACCEPT’ means that it is futile to continue
and more data are unlikely to lead us to reject H0. Conser-
vative practice in clinical trials calls for two-sided tests;
that is, reject if treatment A effects are significantly larger
or smaller than treatment B effects. Thus, with a futility
stopping option, the study continues unless the absolute
treatment difference is either too large or too small.Ordinal scales
SLE is a multisystem disease with protean and varied
manifestation and symptoms. As a consequence, meas-
uring outcome has relied on multidimensional scales or
composite indices for SLE, all of which yield ordinal data
at best. Some scales are not even ordinal. The classic ex-
ample, the ad hoc visual analog scale, asks a patient to
mark a point on a 10-cm line to indicate, for example,
their level of pain, with 0 for ‘no pain’ and 10 for ‘worst
pain ever’ anchoring the ends of the line [12]. Each
patient has a unique scale and their scales are logically
incongruous; that is, patients who mark ‘5’ need not
have the same level of pain. Similarly, the five-point
Likert scale from ‘strongly agree’ to ‘strongly disagree’ is
incongruous across people [13]. To make evaluation
practical and for simplicity sake, we ignore such errors
in measurement, although there are statistical methods
that address this problem [14] (Table 1).Table 3 Raw systemic lupus activity measure scores divided
into four categories
Raw systemic lupus activity measure score
0 to 20 21 to 40 41 to 50 51 to 84
Disease severity 1 2 3 4
Description Negligible Mild Moderate SevereRecalibrating an ordinal scale
We can simplify an ordinal scale to form a binary out-
come. This was done, for example, in the Belimumab trial,
where success was defined as a reduction of four or more
in the Safety of Estrogens in Lupus Erythematosus-
SLEDAI score [15]. This simple approach discardsinformation, but the clinical importance of a reduction of
four may vary depending on the baseline score.
Another instructive example comes from stroke studies
in which the modified Rankin Scale is often used to
evaluate patients 90 days after an incident of stroke [16]
(Table 2).
Many studies reduce the modified Rankin Scale score
to a binary outcome with success defined as a score of 2
or less, but others have used 1 or less [17]. Experts do
not always agree on how to define success. One way to
retain more detail is to assign clinically meaningful
utilities to each value to allow comparison of mean treat-
ment utilities as if the outcome measure were a con-
tinuous interval scale [18].
Response criteria for systemic lupus
erythematosus
The American College of Rheumatology (ACR) orga-
nized a working group in 2002 to develop standards for
the evaluation of therapeutic interventions for patients
with SLE [19]. It attempted to develop a data-driven
consensus on meaningful clinical change over time ‘to
help investigators develop sample size estimates based
on meaningful effect sizes and to gauge the clinical rele-
vance of any observed change in disease activity’. Experts
on SLE used a secure web-based survey to review a sam-
ple of actual patient histories chosen from 310 carefully
abstracted, longitudinal, and uniformly formatted SLE
patient case histories, over a 2- or 6-month interval. The
cases were assessed by several experts as to the degree
of change—either ‘worse’, ‘no change’ or ‘improved’ and
blinded to the independently scored disease activity
measures listed in Table 1. For example, if a change, Δ,
in a scale was 4 units, then the aggregated data allowed
estimation of the three probabilities (P) that add up to
1.0: P(Worse|(Δ = 4)) = 0.82, P(No change|(Δ = 4)) = 0.12,
and P(Better|(Δ = 4)) = 0.06.
Table 4 Systemic lupus activity measure score categories
recalibrated to have equal width
Raw SLAM categories 0 to 20 21 to 40 41 to 50 51 to 84
Uniform width categories 0 to 20 21 to 40 41 to 60 61 to 80
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interpreted a rise of 4 units for this particular scale as
worsening disease. The study did not determine whether
or not rises from different baseline values, such as 0 to
4, 1 to 5, and 2 to 6, represented similar levels of clinical
change , but suggested that it sufficed to consider only
Δ = 4. Also, Fig. 2 of the ACR paper [19] supported a
symmetric interpretation, that a decrease of 4 implied
clinical improvement.
Increasing the uniformity in levels of clinical
change
A general approach is to recalibrate an ordinal scale to
make changes of the same size more clinically uniform.
The following illustrative example indicates how one
might recalibrate SLAM scores that vary from 0 to 84,
but could be applied to any ordinal scale (SLE or not).
The interval width of 20 is arbitrary. First, ask a group
of experts to construct intervals that map the raw scores
into a few categories of increasing severity (Table 3).
The underlying assumption is that the changes from
negligible to mild, from mild to moderate, and from
moderate to severe are roughly equal in terms of clinical
importance. Next, recalibrate the raw scores so that each
category is 20 units wide (Table 4).
In Table 4, the raw scores from 41 to 50 then stretch
into scores from 41 to 60 while raw scores from 51 to
84 squeeze into scores from 61 to 80. Hence, we stretch
and squeeze the raw scale to give differences between
values a more similar clinical meaning. Then the differ-
ence between mean uniform-width SLAM scores should
have a more clinically consistent meaning than the
difference between mean raw scores. While simple to
describe, such a process requires a consensus among ex-
perts. The example above outlines the process, but a
genuine effort by experts would require a major effort.
Ideally, the experts would make uniform-width intervals
in several distinct ways to check that a significant statis-
tical result was not merely an artifact of the process. ForFig. 3 An example of the pattern of enrolment in a group sequential trialexample, the range of scores could be divided into six
categories.A hypothetical systemic lupus erythematosus
example
A 12-month study compares two SLE treatments, A and
B, using the smoothed SLAM score as the outcome
measure. The study enrolls a total of 192 subjects, 96
per study arm. Each patient is treated for 3 months and
the 3-month SLAM score is the primary outcome. Be-
ginning at time 0, during the first 3 months 64 patients
are enrolled, 32 receive A and 32 receive B. From the be-
ginning of month 3 to the end of month 5 and then
from the beginning of month 6 to the end of month 8
exactly the same enrolment occurs. During the last
3 months no subjects enroll. By the end of the year the
last patient enrolled will have completed treatment.
Figure 3 illustrates this enrolment pattern. For simpli-
city, we assume no drop outs.
The interim analysis tests are right-shifted along the
time axis. The test at the beginning of month 6 can only
compare the outcomes of the first 64 patients enrolled
during the first 3 months, the last of whom completed
3 months' of follow-up at the end of month 5. The test
at 9 months evaluates 128 subjects and the test at
12 months evaluates 192 subjects.
To add a realistic concern, suppose the experts under-
took the study hoping that a new treatment A would
prove superior to a standard treatment B. In terms of
SLAM scores, a lower score is superior. Then, if during
the study the results went in the wrong direction (sub-
jects on treatment B had lower scores) and the observed
mean difference, d ¼ b−a < 0, we might stop the trial
for futility. Typically, we use a conservative two-sided
null hypothesis (H0) and a two-sided alternative hypoth-
esis (HA). Assuming differences go in the direction
hoped for by the experts, then with type I error = 5 %
and power = 90 % under an O’Brien-Fleming design, the
three cutoff Z-values to reject H0 would be 3.47, 2.45,
and 2.00, with corresponding type I errors of 0.0005,
0.014, and 0.045. Unless the true difference in treatment
effects were much larger than expected, the study would
be unlikely to end early.
To illustrate futility, when treatment B has the lower
SLAM scores, cutoff Z-values to stop early and accept
Note: This article is part of the series ‘Measuring meaningful
change in lupus clinical trials’, edited by Matthew Liang and
Chan-Bum Choi. Other articles in this series can be found at
http://arthritis-research.com/series/trials
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and −0.013 at the second interim analysis. No futility
value is needed for the final analysis.
This example illustrates some of the details that enter
a simulation for a 1-year study design with an option to
stop for futility. Using the R language we randomly gen-
erated 2000 data sets for each hypothesis. We assumed
that the recalibrated SLAM score varied from 0 to 80
and has a standard deviation of 6. Under H0 (no differ-
ence) we might expect both groups A and B to have
mean recalibrated SLAM scores of 14 and both would
decline to mean scores of 10 after 1 year. Under HA
(alternative) the superior treatment A would decline to
9, making the final mean difference 10 – 9 = 1. We also
needed to specify the correlation between baseline and
subsequent results and a realistic effect size. Under HA,
a single simulation yielded z-scores of 1.97, 2.51, and
2.09 at months 6, 9, and 12 that have associated P-values
of 0.048, 0.012, and 0.037. Recall that the cutoff Z-values
to reject H0 are 3.47, 2.45, and 2.00 with corresponding
type I errors of 0.0005, 0.014, and 0.045. Then, under
HA for this scenario, the study would correctly reject
H0 at the second interim analysis, since the z-score
2.51 > cutoff 2.45. These observed z-scores would not
have stopped the study for futility. Repeating the simula-
tion 2000 times under H0 provides an approximation of
type I error, the proportion of times we stop and reject
H0. Doing the same under HA provides an estimate of
power, the proportion of times we stop and reject H0.
Discussion
The definition, a priori, of what constitutes a clinically
important improvement and worsening disease activity
by the ACR committee [18] is a milestone in the devel-
opment of more efficient and safer trials in SLE.
Methods such as uniform-width intervals can make an
ordinal measure of SLE disease activity more like an
interval scale suitable for group sequential trials. Several
uniform-width alternatives should be examined. When
this seems too arduous, then coarsening the ordinal out-
come into a binary outcome gives up some information,
but opens up group sequential designs.
The advances in computing have made available a vast
array of possible study designs that can only be compared
using extensive simulations. The highly flexible Bayesian
designs also require information about observed distribu-
tions from previous trials. The O’Brien-Fleming designs
can be implemented without simulation using published
tables [5] and relatively few new concepts.
The US Food and Drug Administration (FDA) has
taken a conservative approach to randomized clinical
trials focusing on type I error. When FDA approval is
not an issue, other criteria may matter more. For ex-
ample, a hospital may wish to save money by using theleast expensive of medications that appear almost
equally effective. The decision might give great weight to
potential side effects or to finding the subgroups of
patients who best tolerate each medication.
Sequential designs are a type of adaptive design. Adap-
tive designs deal with issues that may arise during a trial,
such as poor recruitment, serious protocol violations,
and unanticipated rates of adverse events [8]. Adaptive
designs require pre-specified options, such as plans to
modify dosage, drop study arms, change the random
allocation, and change eligibility criteria during the trial.
In conclusion, group sequential randomized clinical
trials may save time and resources. Modifying ordinal
outcome scales for SLE, such as SLAM, BILAG, and
SLEDAI, to give them interval properties, could facilitate
the adoption of such study designs for comparing treat-
ments for SLE.Abbreviations
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